The company sold 33.5 million shares at $20 each on Tuesday night, exceeding the projected range of $17 to $19. Investor momentum pushed the stock as high as $33.40 during the session.

Beyond the public offering, Parabilis finalized a concurrent private placement with Regeneron Pharmaceuticals. The collaboration partner acquired approximately 4.2 million shares at a price of $18 per share, further signaling institutional confidence in the company’s pipeline.